Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4C | Q9H3R0 | 17/20 | 0.58 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.48 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.48 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.42 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.40 |
| ▸ | KDM5A | P29375 | 1/20 | 0.40 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29600940 | 1.00 | KDM4C (0.58) | KDM4CHDAC1HDAC2ROCK1MAPK14 | |
| SCHEMBL24437135 | 0.92 | KDM4C (0.52) | KDM4CHDAC1HDAC2ROCK1MAPK14 | |
| SCHEMBL29601435 | 0.92 | KDM4C (0.52) | KDM4CHDAC1HDAC2ROCK1MAPK14 | |
| SCHEMBL29601258 | 0.90 | KDM4C (0.57) | KDM4CHDAC1HDAC2MAPK14 | |
| SCHEMBL24437308 | 0.90 | KDM4C (0.57) | KDM4CHDAC1HDAC2MAPK14 | |
| SCHEMBL29601495 | 0.90 | KDM4C (0.48) | KDM4CHDAC1HDAC2MAPK14 | |
| SCHEMBL24437216 | 0.90 | KDM4C (0.48) | KDM4CHDAC1HDAC2MAPK14 | |
| SCHEMBL24437151 | 0.88 | CNR1 (0.48) | KDM4CROCK1 | |
| SCHEMBL24437270 | 0.85 | KDM4C (0.51) | KDM4CHDAC1HDAC2MAPK14 | |
| SCHEMBL29601463 | 0.85 | KDM4C (0.51) | KDM4CHDAC1HDAC2MAPK14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220153735-A1 | Orai Channel Inhibitors | BETH ISRAEL DEACONESS MEDICAL CENTER, INC. | 2022-05-19 | — | — | US | disclosed |
| US-20220153735-A1 | Orai Channel Inhibitors | BETH ISRAEL DEACONESS MEDICAL CENTER, INC. | 2022-05-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220153735-A1 | Orai Channel Inhibitors | ORAI2, ORAI1, ORAI3 | KDM4C 3959/4885HDAC1 1483/4885HDAC2 1052/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.